CollPlant Biotechnologies Ltd. (CLGN) stock forecast & analysis
0.3879
NasdaqCM · USD
Up: +0.0299, +8.4%
1 analysis
- Open
- 0.3800
- Previous close
- 0.3580
- Day range
- 0.3610 – 0.9600
- 52-week range
- 0.2640 – 3.18
- Volume (shares)
- 180.98M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 18.91M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.68
- Market cap
- 7.33M
Market Scanner’s AI analysis of CollPlant Biotechnologies Ltd. (CLGN), updated September 2026: CollPlant Biotechnologies' acquisition of LightSolver and recent share activity contrasted with significant revenue decline and long-term stock underperformance.
Summary
CollPlant Biotechnologies' acquisition of LightSolver and recent share activity contrasted with significant revenue decline and long-term stock underperformance.
Recent analyses for CollPlant Biotechnologies (CLGN) covered its strategic acquisition of LightSolver, marking an entry into supercomputing and photonic computing markets. The reports also noted significant corporate actions including a share resale prospectus and a private placement. These developments were examined alongside a substantial year-over-year quarterly revenue decline and a long-term stock price underperformance relative to its 200-day moving average.
CLGN news & sentiment
News coverage highlighted CollPlant Biotechnologies' significant strategic shift with the acquisition of LightSolver and related financial activities, signaling substantial corporate action. Social media discussion focused on the stock's recent price movements and technical indicators, noting upward trends and buying pressure alongside concerns about long-term underperformance and revenue decline.
CLGN technical picture
CollPlant Biotechnologies' stock showed strong recent upward momentum, trading above its 50-day moving average with positive medium-term trends indicated by momentum oscillators. However, the price remained significantly below its 200-day moving average, reflecting a long-term downtrend, while high buying pressure was noted.
Fundamentals
CollPlant Biotechnologies (CLGN) reported a significant year-over-year quarterly revenue decline and negative profit margins. The company's liquidity appears adequate based on its current and quick ratios, with substantial cash reserves on hand.
Factors discussed — upside
- Recent 7-day and 30-day stock price increases.
- Price trading above 50-day simple moving average.
- Relative Strength Index (RSI) approaching overbought but within a healthy uptrend range.
- Extremely high Money Flow Index (MFI) suggesting significant buying pressure.
- Acquisition of LightSolver to enter supercomputing and photonic computing markets.
Factors discussed — risks
- Significant year-over-year quarterly revenue decline of -96.4%.
- Negative TTM operating margin of -42.67%.
- Negative gross profit for the latest quarter and TTM.
- Stock price significantly below 200-day simple moving average.
- Filing of prospectus for resale of 31 million shares.
- Strategic acquisition
- Financial performance
- Stock momentum
- Corporate actions
Summary updated .
CLGN technical indicators
Common technical indicators for CLGN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.33 | Price above |
| 10-day exponential moving average | 0.33 | Price above |
| Relative strength index (14-day) | 63.32 | Neutral |
| MACD line (12/26/9) | 0.0025 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.27 – 0.37 | Price above the upper band |
Analyses
Recent CLGN.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for CollPlant Biotechnologies Ltd.?
- The bull case for CollPlant Biotechnologies (CLGN) centers on its strategic acquisition of LightSolver, which provides entry into the supercomputing and photonic computing markets. Recent stock performance has shown positive momentum with significant short-term price increases and trading above its 50-day moving average, supported by strong buying pressure indicated by the Money Flow Index.
- What are the risks for CollPlant Biotechnologies Ltd.?
- Risks for CollPlant Biotechnologies (CLGN) include a substantial year-over-year quarterly revenue decline and persistent negative gross and operating margins. The stock price remains significantly below its 200-day moving average, indicating long-term underperformance, and the company has filed a prospectus for the resale of a large number of shares.
- Is CollPlant Biotechnologies Ltd. bullish or bearish?
- Recent AI analyses of CollPlant Biotechnologies Ltd. examined factors on both sides. Discussed upside: The bull case for CollPlant Biotechnologies (CLGN) centers on its strategic acquisition of LightSolver, which provides entry into the supercomputing and photonic computing markets. Recent stock performance has shown positive momentum with significant short-term price increases and trading above its 50-day moving average, supported by strong buying pressure indicated by the Money Flow Index. Discussed risks: Risks for CollPlant Biotechnologies (CLGN) include a substantial year-over-year quarterly revenue decline and persistent negative gross and operating margins. The stock price remains significantly below its 200-day moving average, indicating long-term underperformance, and the company has filed a prospectus for the resale of a large number of shares. These are descriptive observations, not a recommendation.
- What is the latest sentiment on CollPlant Biotechnologies Ltd.?
- News coverage highlighted CollPlant Biotechnologies' significant strategic shift with the acquisition of LightSolver and related financial activities, signaling substantial corporate action. Social media discussion focused on the stock's recent price movements and technical indicators, noting upward trends and buying pressure alongside concerns about long-term underperformance and revenue decline.
- Bundles used
- gemini-low-v2
Run a fresh CLGN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every CLGN.US report already in the library